DIRS.INFO The most relevant business & tech news

He was tied at 6-under 136 with Kevin Streelman (72), tour rookie Chandler Phillips (68), Brendon Todd (69) and Mackenzie Hughes (68). “There's a reason that so many players rave about this course,” Cink said. Only six shots separated the players sharing the lead to the players making the cut on the number. For Spieth, it was the first time since 2017 that he missed the cut at regular PGA Tour events in consecutive weeks (Players Championship, Byron Nelson). “I get another chance to learn some really great lessons and maybe some hard lessons this week again.”___

Persons: — Stewart Cink, There's, Kevin Streelman, Chandler Phillips, Brendon Todd, Mackenzie Hughes, “, ” Cink, Streelman, Phillips, Justin Thomas, Lucas Glover, ” Thomas, ”, —, — Jordan Spieth, Sam Burns, Brian Harman, Tony Finau, Keegan Bradley, Byron Nelson, Todd, ” Todd, I’m Organizations: PGA, Augusta National, “ Locations: PALM HARBOR, Fla, Innisbrook, British, Arizona, Cologuard, Tucson

☆ This U.S. biotech stock is up 90% this year and will continue to soar, fund manager says
▼ + stars: | 2023-06-23 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Shares of U.S. biotech firm Exact Sciences have surged by almost 90% this year. But the run may not be over just yet, according to fund manager Dani Saurymper. Earlier this week it said its next-generation screening test, Cologuard 2.0, showed a 30% lower false positive rate for detecting the disease in a study compared to its already approved test. This is where Exact Sciences fits in. Saurymper believes that the stock has corrected and has a significant runway ahead.

Persons: Dani Saurymper, Saurymper, CNBC's, EXAS, Kyle Mikson, Canaccord Genuity, CNBC's Arabile, it's Organizations: Sciences, Nasdaq, Companies, FDA

☆ Exact Sciences' shares pop on positive Cologuard trial results
▼ + stars: | 2023-06-20 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailExact Sciences' shares pop on positive Cologuard trial resultsKevin Conroy, Exact Sciences CEO, joins 'Fast Money' to discuss Exact Sciences latest trial results for its colo-rectal cancer tests, Cologuard.

Persons: Kevin Conroy Organizations: Sciences

☆ Stocks making the biggest moves premarket: Accenture, Winnebago, Maxar Technologies and more
▼ + stars: | 2022-12-16 | by ( Peter Schacknow | ) www.cnbc.com time to read: +2 min

Accenture issued a revenue range for the current quarter whose midpoint is below current consensus and said the stronger U.S. dollar will impact its fiscal 2023 results by 5%. Maxar Technologies (MAXR) – The satellite owner and operator's shares more than doubled in the premarket after it agreed to be acquired by private equity firm Advent International for $53 per share. Guardant Health (GH) – Guardant shares plunged 33.4% in the premarket following trial results for its DNA blood test for colorectal cancers. Adobe also issued upbeat current quarter guidance. U.S. Steel (X) – U.S. Steel issued better-than-expected current quarter guidance and said commercial demand for steel is on the upswing in the U.S.

☆ Guardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 39%
▼ + stars: | 2022-12-15 | by ( Deena Beasley | ) www.reuters.com time to read: +2 min

Cologuard, a stool-based DNA test, identifies 92% of colorectal cancers and 42% of pre-cancerous polyps, according to data from Exact Sciences (EXAS.O), which markets the test. Guardant said that a subsequent colonoscopy ruled out colon cancer in 10% of people who tested positive with its DNA blood test. "This is a huge unmet clinical need," Talasaz said of a blood test for detecting colon cancer. "There are still 50 million people out there who are not complying with colorectal cancer screening." Guardant is currently enrolling patients in a different trial of its DNA blood test for detecting lung cancer, Talasaz said.

☆ A Silicon Valley biotech just showed a simple blood test can detect a hidden and deadly type of cancer. But the results fell short of investors' hopes.
▼ + stars: | 2022-12-15 | by ( Leah Rosenbaum | ) www.businessinsider.com time to read: +7 min

Guardant Health said that its blood test to screen for cancer caught 83% of colorectal cancer cases. On Thursday, Silicon Valley-based biotech Guardant Health announced that its blood-based cancer screening test correctly caught colorectal cancer cases in 83% of people who had the disease. The company already has several products on the market, including Guardant360CDx, an FDA-approved blood test to test cancer genomic markers that could help show what treatments the cancers are susceptible to. Colonoscopies are still the gold standard of colorectal cancer screening, despite involving sedation and hours of unpleasant physical preparation. And while colorectal cancer is the first cancer that is being studied for a blood-based screening, it certainly won't be the last.

Following the news that actor Kirstie Alley died of colon cancer at age 71, several doctors and cancer specialists urged people to get the recommended screenings for the disease. Alley's manager confirmed to NBC News on Tuesday that the actor died of colon cancer. Colorectal cancer is the fourth-most common form of cancer in the U.S. and the second-most deadly behind lung cancer. The National Cancer Institute estimates that around 151,000 cases of colorectal cancer will be diagnosed this year. Colon cancer can be difficult to diagnose, however, since symptoms can resemble those of other conditions like hemorrhoids or irritable bowel syndrome.

Search resuls for: "Cologuard"

7 mentions found